Healthcare - Biotechnology - NYSE - US
$ 6.37
-12.9 %
$ 367 M
Market Cap
-0.35
P/E
CASH FLOW STATEMENT
-296 M
OPERATING CASH FLOW
-80.7 M
INVESTING CASH FLOW
-3.22 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Ginkgo Bioworks Holdings, Inc.
| Net Income | -893 M |
| Depreciation & Amortization | 71.6 M |
| Capital Expenditures | -40.8 M |
| Stock-Based Compensation | 230 M |
| Change in Working Capital | 29.8 M |
| Others | 248 M |
| Free Cash Flow | -336 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2001 | |
|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||
| Net Income | (892.9) | (2 106.4) | (1 836.6) | (126.7) | (119.9) | (2 106.4) |
| Depreciation & Amortization | 71.6 | 44.4 | 29.1 | 13.9 | 10.8 | 44.4 |
| Deferred Income Tax | (0.8) | (14.6) | 30.2 | 4.1 | 54.7 | (14.6) |
| Stock Based Compensation | 229.9 | 1 930.6 | 1 606.0 | 0.5 | 0.8 | 1 930.6 |
| Other Operating Activities | 266.9 | (69.3) | (20.9) | (1.1) | (1.6) | (55.0) |
| Change in Working Capital | 29.8 | (37.0) | (61.5) | (26.5) | 10.6 | 55.0 |
| Cash From Operations | (295.5) | (252.2) | (253.8) | (135.8) | (44.7) | (145.9) |
| INVESTING CASH FLOW | ||||||
| Capital Expenditures | (40.8) | (52.3) | (56.5) | (57.8) | (22.2) | 0 |
| Other Items | (39.9) | (15.1) | (16.7) | (9.3) | (52.4) | 0 |
| Cash From Investing Activities | (80.7) | (67.4) | (73.3) | (67.1) | (74.6) | 0 |
| FINANCING CASH FLOW | ||||||
| Common Stock Repurchased | 23 K | 0 | (25.0) | 0 | (0.4) | 0 |
| Total Debt Repaid | (1.3) | (1.2) | (1.1) | (0.7) | 198.6 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.9) | (4.0) | 1 560.3 | 91.1 | 212.2 | 0 |
| Cash From Financing Activities | (3.2) | 95.3 | 1 534.1 | 90.3 | 410.4 | 0 |
| CHANGE IN CASH | ||||||
| Net Change In Cash | (380.0) | (223.3) | 1 207.1 | (112.6) | 291.1 | (145.9) |
| FREE CASH FLOW | ||||||
| Free Cash Flow | (336.3) | (304.5) | (310.3) | (193.7) | (66.9) | (145.9) |